Abstract

Background: Topotecan monotherapy is an effective treatment in recurrent, metastatic platinum-resistant epithelial ovarian cancer, but this regimen has not been well studied in Vietnam. This study aimed to tackle this problem. Methods: Study of 32 ovarian cancer patients in recurrent or metastatic setting, progressed after platinum-based chemotherapy were treated with Topotecan at Hanoi Oncology Hospital, National Cancer Hospital and Hanoi Medical University Hospital between January 2016 and July 2019. Results: Mean age was 58.6 ± 7 (43 – 72). Most patients had been treated with more than one regimen. 51.3% of all patients gained clinical benefit. Median progresssion free survival was 6.1 months. Median overall survival was 11.8 months. Most toxicities was in grade 1 or 2 with the most common complaint was fatigue. Conclusion: Topotecan is a considerable option in platinum-resistant ovarian cancer with certain clinical benefits.